- Home
- ESEA vs TNXP Comparison
ESEA vs TNXP Comparison
Compare ESEA & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESEA
- TNXP
- Stock Information
- Founded
- ESEA 2005
- TNXP 2007
- Country
- ESEA Greece
- TNXP United States
- Employees
- ESEA N/A
- TNXP N/A
- Industry
- ESEA Marine Transportation
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- ESEA Consumer Discretionary
- TNXP Health Care
- Exchange
- ESEA Nasdaq
- TNXP Nasdaq
- Market Cap
- ESEA 369.5M
- TNXP 365.8M
- IPO Year
- ESEA 2006
- TNXP N/A
- Fundamental
- Price
- ESEA $51.44
- TNXP $39.01
- Analyst Decision
- ESEA Strong Buy
- TNXP Buy
- Analyst Count
- ESEA 1
- TNXP 1
- Target Price
- ESEA $62.00
- TNXP $70.00
- AVG Volume (30 Days)
- ESEA 42.5K
- TNXP 1.4M
- Earning Date
- ESEA 08-05-2025
- TNXP 08-15-2025
- Dividend Yield
- ESEA 5.05%
- TNXP N/A
- EPS Growth
- ESEA 21.86
- TNXP N/A
- EPS
- ESEA 18.62
- TNXP N/A
- Revenue
- ESEA $222,525,034.00
- TNXP $10,041,000.00
- Revenue This Year
- ESEA $7.22
- TNXP $22.87
- Revenue Next Year
- ESEA $1.75
- TNXP $711.66
- P/E Ratio
- ESEA $2.78
- TNXP N/A
- Revenue Growth
- ESEA 14.62
- TNXP N/A
- 52 Week Low
- ESEA $24.58
- TNXP $6.76
- 52 Week High
- ESEA $53.05
- TNXP $130.00
- Technical
- Relative Strength Index (RSI)
- ESEA 63.77
- TNXP 46.37
- Support Level
- ESEA $50.61
- TNXP $41.64
- Resistance Level
- ESEA $53.05
- TNXP $50.39
- Average True Range (ATR)
- ESEA 1.51
- TNXP 3.97
- MACD
- ESEA -0.13
- TNXP -1.15
- Stochastic Oscillator
- ESEA 68.12
- TNXP 22.73
About ESEA Euroseas Ltd. (Marshall Islands)
Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes, providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.